- About Us
- Advertise
- Contact Us
- CureToday.com
- CancerNetwork.com
- OncLive.com
- Do Not Sell My Information
- Privacy
- Terms & Conditions
© 2021 MJH Life Sciences™ , Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
Genitourinary Cancers | Clinical
TAK-700 Achieves Limited Overall Survival Improvement in mHSPC
June 08, 2021
Data from the phase 2 the phase 3 SWOG S1216 presented during the ASCO Annual Meeting shows numerical overall survival improvement with he experimental combination that missed the threshold for statistical significance.
Urothelial Cancer Guidelines Are Updated to Include Immune Checkpoint Inhibitors
May 17, 2021
Immunotherapies are now accepted treatments in the maintenance and second-line settings for patients with metastatic urothelial cancer and in the setting of superficial UC–carcinoma in situ with prior intravesical therapy, according to updated NCCN guidelines
Durvalumab Plus Radiation Therapy Demonstrates Efficacy in Bladder Cancer
May 15, 2021
Yousef Zakharia, MD, discusses the results of a phase 2 trial investigating concurrent durvalumab and radiation therapy followed by adjuvant durvalumab in patients with localized urothelial cancer of bladder.
Roundtable Discussions: Choudhury Leads Debate on How to Treat Nonmetastatic Prostate Cancer
May 12, 2021
During a virtual Targeted Oncology Case-Based Roundtable event, Atish D. Choudhury, MD, PhD, discussed methods for treating patients with nonmetastatic prostate cancer with a group of peers.
Dorff Discusses the CARD Trial in Metastatic Castrate- Resistant Prostate Cancer
May 07, 2021
During a virtual Targeted Oncology Case-Based Roundtable event, Tanya Dorff, MD, discussed the case of a 75-year-old man with metastatic castration-resistant prostate cancer.
Roundtable Discussion: Smith Leads a Discussion on the Utility of Genomic Testing in Prostate Cancer
May 03, 2021
During a Targeted Oncology Case-Based Roundtable event, Matthew Smith, MD, PhD, discussed genomic testing in prostate cancer with a group of peers.
FDA Grants Priority Review to Adjuvant Nivolumab for High-Risk MIUC
April 30, 2021
The FDA has accepted a Biologics License Application for nivolumab for the adjuvant treatment of patients with surgically resected, high-risk muscle-invasive urothelial carcinoma and granted it Priority Review.
Ornstein Discusses the Use of Cabozantinib in Clear Cell Renal Cell Carcinoma
April 29, 2021
During a virtual Targeted Oncology Case-Based Roundtable event, Moshe Ornstein, MD, MA, discussed the case of a 59-year-old patient with clear cell renal cell carcinoma.
The Need for Novel Neoadjuvant Therapies in HCC
April 28, 2021
Thomas Marron, PhD, MD, discusses the need for effective neoadjuvant therapies in hepatocellular carcinoma.
ODAC Says Yes to Continued Approval of Atezolizumab for Cisplatin-Ineligible Locally Advanced or Metastatic UC
April 28, 2021
The FDA’s Oncologic Drug Advisory Committee voted 10 to 1 to continue the accelerated approval of atezolizumab for the frontline treatment of patients with urothelial cancer who are ineligible for cisplatin.